Abstract: Embodiments herein include implantable medical devices including chemical sensors with bioerodible masking layers to allow for staged activation of the sensors. In an embodiment, an implantable medical device includes a substrate defining wells and a first chemical sensor and a second chemical sensor disposed within separate wells of the substrate. The first chemical sensor and the second chemical sensor can be configured to detect one or more analytes. The device can include a first bioerodible masking layer disposed over the second chemical sensor, sealing off the second chemical sensor. The device can further include a protective planarization layer disposed over at least one of the first chemical sensor and the second chemical sensor such that the outermost surface of the medical device over the first sensor is flush with the outermost surface of the medical device over the second sensor. Other embodiments are also included herein.

Abstract: Embodiments herein relate to systems and methods for combining data from different types of sensors. In an embodiment, a medical system is included. The medical system can include a first sensor configured to produce a first value for an analyte and a second sensor different than the first sensor, the second sensor configured to produce a second value for the analyte. The medical system can also include a controller configured to receive the first and second values. The controller can create a blended analyte value from the first value and second value. Other embodiments are included herein.

Abstract: Embodiments herein relate to chemical sensors for detecting a physiological analyte. In an embodiment, an implantable medical device including a chemical sensor for detecting an ion concentration in a bodily fluid is provided. The chemical sensor can include a sensing element having an outer barrier layer forming a top, a bottom, and opposed sides, where the top of the outer barrier layer can be created from a polymeric matrix permeable to sodium ions, potassium ions, and hydronium ions. An active agent can be disposed within the top of the outer barrier layer, the active agent having anti-inflammatory effects. The chemical sensor can include an optical excitation assembly configured to illuminate the sensing element. The chemical sensor can also include an optical detection assembly configured to receive light from the sensing element. Other embodiments are also included herein.

Abstract: A thickness measurement system includes a composite carrier assembly and a thickness sensor system. The composite carrier assembly includes a sample carrier and a gauge standard carrier. The sample carrier and gauge standard carrier are configured to simultaneously support a sample and a gauge standard, respectively. The thickness sensor system is configured to generate a signal representative of a thickness of the sample and to be calibrated with the gauge standard while the sample and the gauge standard are simultaneously supported by the sample carrier and the gauge standard carrier, respectively.

Abstract: An infrared thermometer adapter for a mobile device having a housing, an aperture on the housing through which infrared radiation emitted or reflected from a target object is able to pass to an infrared sensor, an electrical plug extending rearward from the housing configured to electrically interconnect with an audio jack on the mobile device, and electronic circuitry adapted for transmitting sensor detection signals from the sensor through the mobile device audio jack so that application software downloaded and running on the mobile device is able to convert the transmitted sensor detection signals into digital data for display on the mobile device display.

Abstract: A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-?, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: A gas detector adapter for a mobile device having a housing, a inlet on the housing through which ambient air is able to pass for detection of a gas such as carbon monoxide by a carbon monoxide detection sensor, an electrical plug extending rearward from the housing configured to electrically interconnect with an audio jack on the mobile device, and electronic circuitry adapted for transmitting sensor detection signals from the sensor through the mobile device audio jack so that application software downloaded and running on the mobile device is able to convert the transmitted sensor detection signals into digital data for display on the mobile device display.

Abstract: A multifunction testing and measuring device having a probe body with an elongated portion extending outward from a rearward main body portion to a hook-shaped forward end, the hook-shaped end useful for isolating a conductor under test, a slide closure member adapted to slide longitudinally forward from a rearward open position to a forward closed position, the closed position useful to capture the conductor under test within a space encircled by the combination of the hook-shaped end, the closed slide closure member, and the rearward main body, with the space encircled including a current sensing zone, and having test leads integral to and stowable on the main body. The multi tester comprises circuitry adapted for detecting a magnetic flux generated by an electric current passing through the conductor under test positioned within the current sensing zone, for sensing current and inrush current, as well as selectably measuring voltage, continuity, and resistance between the test leads.

Abstract: Embodiments herein include systems and methods for detecting, predicting and/or assessing acute kidney injury. In an embodiment, a monitoring system to detect acute kidney injury is included. The monitoring system can include a sensor circuit configured to collect renal data including at least one of systemic renal data, direct renal data, urinary tract data, and renal-relevant extracorporeal data. The monitoring system can also include a memory circuit to store collected renal data, an evaluation circuit to assess renal status, and a telemetry circuit. The evaluation circuit can determine whether acute kidney injury has occurred or is likely to occur by comparing the renal data to at least one of threshold values, personal historical values, patient population values and patterns indicative of acute kidney injury. The evaluation circuit can initiate a warning notification if acute kidney injury has occurred or is likely to occur. Other embodiments are also included herein.

Abstract: A method for providing a verification process for verifying eligibility of a domain name registrant via a verification web interface for a domain name either registered or in the process of registration with a registrar over a communications network.

Abstract: A current measuring device having a probe body with an elongated portion extending outward from a rearward main body portion to a hook-shaped forward end, the hook-shaped end useful for isolating a conductor under test, a slide closure member adapted to slide longitudinally forward from a rearward open position to a forward closed position, the closed position useful to capture the conductor under test within a space encircled by the combination of the hook-shaped end, the closed slide closure member, and the rearward main body, with the space encircled including a current sensing zone, and circuitry adapted for detecting a magnetic flux generated by an electric current passing through the conductor under test positioned within the current sensing zone. A release button for moving the slide closure member serves as a switch to turn on the meter/tester/device when the jaw/slide closure member is opened.

Abstract: A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-?, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: A current measuring device having a probe body with an elongated portion extending outward from a rearward main body portion to a hook-shaped forward end, the hook-shaped end useful for isolating a conductor under test, a slide closure member adapted to slide longitudinally forward from a rearward open position to a forward closed position, the closed position useful to capture the conductor under test within a space encircled by the combination of the hook-shaped end, the closed slide closure member, and the rearward main body, with the space encircled including a current sensing zone, and circuitry adapted for detecting a magnetic flux generated by an electric current passing through the conductor under test positioned within the current sensing zone. A release button for moving the slide closure member serves as a switch to turn on the meter/tester/device when the jaw/slide closure member is opened.

Abstract: Implementations described and claimed herein provide systems and methods for balancing network loads across distinct provider networks using enriched network traffic flow data. In one implementation, network traffic flow data representative of network traffic exchanged between a first provider network and a second provider network is generated. The network traffic flow data is enriched using at least one enrichment feed. A network load indication for the first provider network is calculated using the enriched network traffic flow data. The network load indication is a function of a bandwidth measurement and a distance measurement.

Abstract: A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: Implementations described and claimed herein providing systems and methods for modeling and visualizing interconnection relationships between a first provider network and a partner. In one implementation, a partner of a provider network is defined by at least one interconnection point where network traffic may be exchanged between the provider network and the partner. An interconnection relationship is generated based on the at least one interconnection point. The interconnection relationship is modeled.

Abstract: A thickness measurement system includes a composite carrier assembly and a thickness sensor system. The composite carrier assembly includes a sample carrier and a gauge standard carrier. The sample carrier and gauge standard carrier are configured to simultaneously support a sample and a gauge standard, respectively. The thickness sensor system is configured to generate a signal representative of a thickness of the sample and to be calibrated with the gauge standard while the sample and the gauge standard are simultaneously supported by the sample carrier and the gauge standard carrier, respectively.

Abstract: A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-?, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.